Allopurinol (Zyloprim)

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism: Xanthine oxidase inhibitor.
Route: PO/IV
Extravasation: unknown

For conciseness and simplicity, currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.

Diseases for which it is used

No known antineoplastic properties. Used for tumor lysis syndrome treatment/prophylaxis.

History of changes in FDA indication

  • 1966-08-19: Initial approval

Also known as

  • Brand names: Abloric, Aloprim, Caplenal, Milurit, Zyloprim, Zyloric, Zyoway


  • FLORENCE: Spina M, Nagy Z, Ribera JM, Federico M, Aurer I, Jordan K, Borsaru G, Pristupa AS, Bosi A, Grosicki S, Glushko NL, Ristic D, Jakucs J, Montesinos P, Mayer J, Rego EM, Baldini S, Scartoni S, Capriati A, Maggi CA, Simonelli C; FLORENCE Study Group. FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Ann Oncol. 2015 Oct;26(10):2155-61. Epub 2015 Jul 27. link to original article PubMed NCT01724528